Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NCT ID: NCT06262386
Last Updated: 2024-02-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
358 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-08-01
Study Completion Date
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early relapse. To address this clinical challenge, many studies have focused on understanding the clinicopathologic characteristics associated with an increased risk of early relapse. Despite these efforts, we can identify patients at risk but cannot pinpoint which individuals will actually experience early relapse. Studies on adjuvant therapy have shown improved survival in cases of more advanced disease but have not demonstrated a reduction in early relapse rates.
In our preliminary analysis of previous study data, we observed that patients with a smaller reduction in circulating tumor cells (CTCs) within the first three days after surgery, followed by an increase on the third-day post-operation, are more likely to experience early relapse during regular monitoring. This pattern may be indicative of minimal residual disease. By combining trends in circulating tumor cell variations with pathologic characteristics, we aim to select patients for adjuvant therapy who are at high risk of developing early relapse.
The objective of our study is to employ screening based on circulating tumor cell dynamics and pathologic features to identify patients likely to experience early relapse and to assess the effectiveness of adjuvant therapy in these cases.
In our preliminary analysis of previous study data, we observed that patients with a smaller reduction in circulating tumor cells (CTCs) within the first three days after surgery, followed by an increase on the third-day post-operation, are more likely to experience early relapse during regular monitoring. This pattern may be indicative of minimal residual disease. By combining trends in circulating tumor cell variations with pathologic characteristics, we aim to select patients for adjuvant therapy who are at high risk of developing early relapse.
The objective of our study is to employ screening based on circulating tumor cell dynamics and pathologic features to identify patients likely to experience early relapse and to assess the effectiveness of adjuvant therapy in these cases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer
NCT06250829
Non-small Cell Lung Cancer Stage IB (Resectable)
Non-small Cell Lung Cancer Stage II (Resectable)
Non-small Cell Lung Cancer Stage ⅢA (Resectable)
RECRUITING
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
NCT07256002
Lung Cancer (NSCLC)
ACTIVE_NOT_RECRUITING
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
NCT07170046
Lung Carcinoma
NOT_YET_RECRUITING
A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC
NCT06503042
Non-small Cell Lung Cancer
NOT_YET_RECRUITING
Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients
NCT03721133
Lung Cancer Recurrent
ENROLLING_BY_INVITATION
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For patients with resectable lung cancer, anatomic resection alongside mediastinal lymph node dissection is pivotal in removing all tumor tissue visible on imaging from the patient's body. Despite these efforts, early relapse remains a significant issue. Literature review shows that the early relapse rate varies between 8 to 10%, potentially due to undetectable occult metastasis by imaging modalities, suggesting the presence of minimal residual disease or tumor cells evading the primary site. Limitations in imaging, such as the slice thickness in computed tomography (CT) scans, which range from 0.375 to 0.5 centimeters, can render tumors smaller than the slice thickness invisible. Similarly, tumors smaller than 0.5 cm may not accumulate sufficient F18-Deoxyglucose to be detectable in positron emission tomography (PET) scans. Additionally, tumor cells may migrate to extrapulmonary sites via lymphatic drainage or circulation.
Survival studies have predominantly focused on the pathologic TNM stage, which aggregates different disease presentations with similar survival outcomes. However, the heterogeneity inherent in pathology may help in identifying patients prone to relapse. From a tumor biology perspective, tumor cells may detach from surrounding tissues, becoming more invasive and entering the bloodstream. Circulating tumor cells (CTCs) have been recognized early in cancer stages and are correlated with treatment response, tumor genetic alterations, and survival. Research has combined CT tumor size and CTCs in a malignancy prediction model for suspicious pulmonary lesions, highlighting that CTCs can rebound in patients experiencing early relapse, indicating occult metastases or minimal residual disease.
Systemic adjuvant therapy is considered the best approach to minimize disease relapse in resectable lung cancer patients. Although many studies have sought to identify patients at risk of relapse to improve survival, the presence of intrapulmonary (N1) or mediastinal (N2) lymph node invasion significantly affects survival in non-small cell lung cancer patients. Even tumors smaller than 1 cm carry a risk of lymph node metastases, with respective risks for cT1a, cT1b, and cT1c tumors reported as 3.8%, 16.3%, and 19.6%. Therefore, patients with tumors larger than 1 cm are recommended adjuvant therapy due to the high risk of lymph node involvement. Adjuvant chemotherapy is advised for patients with stages 1b to 3a, showing a 5.4% survival benefit by the fifth postoperative year, although this benefit diminishes in subsequent years. This could be due to adjuvant therapy being administered based on the pathologic stage rather than the likelihood of relapse. Tumor heterogeneity might also influence the response to different therapeutic regimens. Molecular profiling of tumors has identified mutations predicting responses to targeted therapies and elucidated drug resistance mechanisms, offering more precise treatments and improving survival. Targeted and immune therapies have shown improved survival in specific tumor subgroups.
This study aims to utilize trends in CTC variations as a screening tool to identify patients at risk of relapse and prescribe adjuvant therapy to evaluate the therapeutic efficacy and survival impact of CTCs.
Survival studies have predominantly focused on the pathologic TNM stage, which aggregates different disease presentations with similar survival outcomes. However, the heterogeneity inherent in pathology may help in identifying patients prone to relapse. From a tumor biology perspective, tumor cells may detach from surrounding tissues, becoming more invasive and entering the bloodstream. Circulating tumor cells (CTCs) have been recognized early in cancer stages and are correlated with treatment response, tumor genetic alterations, and survival. Research has combined CT tumor size and CTCs in a malignancy prediction model for suspicious pulmonary lesions, highlighting that CTCs can rebound in patients experiencing early relapse, indicating occult metastases or minimal residual disease.
Systemic adjuvant therapy is considered the best approach to minimize disease relapse in resectable lung cancer patients. Although many studies have sought to identify patients at risk of relapse to improve survival, the presence of intrapulmonary (N1) or mediastinal (N2) lymph node invasion significantly affects survival in non-small cell lung cancer patients. Even tumors smaller than 1 cm carry a risk of lymph node metastases, with respective risks for cT1a, cT1b, and cT1c tumors reported as 3.8%, 16.3%, and 19.6%. Therefore, patients with tumors larger than 1 cm are recommended adjuvant therapy due to the high risk of lymph node involvement. Adjuvant chemotherapy is advised for patients with stages 1b to 3a, showing a 5.4% survival benefit by the fifth postoperative year, although this benefit diminishes in subsequent years. This could be due to adjuvant therapy being administered based on the pathologic stage rather than the likelihood of relapse. Tumor heterogeneity might also influence the response to different therapeutic regimens. Molecular profiling of tumors has identified mutations predicting responses to targeted therapies and elucidated drug resistance mechanisms, offering more precise treatments and improving survival. Targeted and immune therapies have shown improved survival in specific tumor subgroups.
This study aims to utilize trends in CTC variations as a screening tool to identify patients at risk of relapse and prescribe adjuvant therapy to evaluate the therapeutic efficacy and survival impact of CTCs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Lung Cancer
Relapse/Recurrence
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient at risk for disease relapse after surgery
1. we utilized a relapse prediction model that combined perioperative variation trends of circulating tumor cells and pathologic characteristics that were collated with relapse
1. circulating tumor cell variation trend: difference between the CTC count on post-operation day 3 and day 1; difference between the CTC count on post-operation day 3 and post-operation
2. pathologic staging 0-1a/ 1b-4
2. patient with high relapse for relapse
* Adjuvant was recommended as NCCN guidelines recommended
Group Type
EXPERIMENTAL
Cisplatin based chemottherapy
Intervention Type
DRUG
adjuvant therapy for high risk patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin based chemottherapy
adjuvant therapy for high risk patient
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients who presented with resectable disease ( Clinical stage 1a to 3a)
2. Patients who received tumor resection
2. Patients who received tumor resection
Exclusion Criteria
1. Pathologic stage greater than stage 3b or 4
2. Pathologic stage less than stage 1a1
3. Could not complete treatment course
4. Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance
2. Pathologic stage less than stage 1a1
3. Could not complete treatment course
4. Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance
Minimum Eligible Age
20 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Science and Technology Council
FED
Sponsor Role
collaborator
Chang Gung Memorial Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ching-Yang Wu
Role: PRINCIPAL_INVESTIGATOR
Chang Gung Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ching-Yang Wu
Taoyuan, , Taiwan
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wu CY, Fu JY, Wu CF, Liu YH, Hsieh MJ, Wu YC, Yang CT, Tsai YH. Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis. Medicine (Baltimore). 2015 Oct;94(40):1. doi: 10.1097/MD.0000000000001700.
Reference Type
RESULT
Boedeker KL, Cooper VN, McNitt-Gray MF. Application of the noise power spectrum in modern diagnostic MDCT: part I. Measurement of noise power spectra and noise equivalent quanta. Phys Med Biol. 2007 Jul 21;52(14):4027-46. doi: 10.1088/0031-9155/52/14/002. Epub 2007 Jun 8.
Reference Type
RESULT
Sun F, Xi J, Zhan C, Yang X, Wang L, Shi Y, Jiang W, Wang Q. Ground glass opacities: Imaging, pathology, and gene mutations. J Thorac Cardiovasc Surg. 2018 Aug;156(2):808-813. doi: 10.1016/j.jtcvs.2018.02.110. Epub 2018 Apr 13.
Reference Type
RESULT
Funama Y, Awai K, Liu D, Oda S, Yanaga Y, Nakaura T, Kawanaka K, Shimamura M, Yamashita Y. Detection of nodules showing ground-glass opacity in the lungs at low-dose multidetector computed tomography: phantom and clinical study. J Comput Assist Tomogr. 2009 Jan-Feb;33(1):49-53. doi: 10.1097/RCT.0b013e31815e6291.
Reference Type
RESULT
Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med. 1992 Jun;33(6):1191-9.
Reference Type
RESULT
Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, Hughes JM. Glucose utilization in vivo by human pulmonary neoplasms. Cancer. 1987 Dec 1;60(11):2682-9. doi: 10.1002/1097-0142(19871201)60:113.0.co;2-h.
Reference Type
RESULT
Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999 Apr;40(4):556-65.
Reference Type
RESULT
Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, Fidler V, Pruim J, Groen HJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000 Jul 27;343(4):254-61. doi: 10.1056/NEJM200007273430404.
Reference Type
RESULT
Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006 Nov 17;127(4):679-95. doi: 10.1016/j.cell.2006.11.001.
Reference Type
RESULT
Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003 Jun;3(6):453-8. doi: 10.1038/nrc1098.
Reference Type
RESULT
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010 Sep;69(3):337-40. doi: 10.1016/j.lungcan.2009.11.019. Epub 2009 Dec 29.
Reference Type
RESULT
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 Jul 24;359(4):366-77. doi: 10.1056/NEJMoa0800668. Epub 2008 Jul 2.
Reference Type
RESULT
O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, O'Byrne KJ. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012 Apr;76(1):19-25. doi: 10.1016/j.lungcan.2011.10.018. Epub 2011 Dec 29.
Reference Type
RESULT
Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012 Feb;9(1):016004. doi: 10.1088/1478-3975/9/1/016004. Epub 2012 Feb 3.
Reference Type
RESULT
Wu CY, Lee CL, Wu CF, Fu JY, Yang CT, Wen CT, Liu YH, Liu HP, Hsieh JC. Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial. Diagnostics (Basel). 2020 Mar 6;10(3):144. doi: 10.3390/diagnostics10030144.
Reference Type
RESULT
Wu CF, Wu CY, Fu JY, Wang CW, Liu YH, Hsieh MJ, Wu YC. Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer. Medicine (Baltimore). 2014 Oct;93(20):e102. doi: 10.1097/MD.0000000000000102.
Reference Type
RESULT
Fu JY, Wan YL, Huang TY, Wu CF, Liu YH, Hsieh MJ, Wu YC, Wu CY. Correction: Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection. PLoS One. 2019 Feb 12;14(2):e0212461. doi: 10.1371/journal.pone.0212461. eCollection 2019.
Reference Type
RESULT
Sonobe M, Date H, Wada H, Okubo K, Hamakawa H, Teramukai S, Matsumura A, Nakagawa T, Sumitomo S, Miyamoto Y, Okumura N, Takeo S, Kawakami K, Aoki M, Kosaka S; The Japan-Multinational Trial Organization. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013 Oct;146(4):788-95. doi: 10.1016/j.jtcvs.2013.04.043. Epub 2013 Jun 27.
Reference Type
RESULT
Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg. 2004 Apr;25(4):502-8. doi: 10.1016/j.ejcts.2004.01.025.
Reference Type
RESULT
Schuchert MJ, Normolle DP, Awais O, Pennathur A, Wilson DO, Luketich JD, Landreneau RJ. Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer. 2019 Feb;128:145-151. doi: 10.1016/j.lungcan.2018.12.026. Epub 2018 Dec 26.
Reference Type
RESULT
Lee G, Lee HY, Jeong JY, Han J, Cha MJ, Lee KS, Kim J, Shim YM. Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma: prognostic significance and survival outcomes. Am J Surg Pathol. 2015 May;39(5):660-6. doi: 10.1097/PAS.0000000000000399.
Reference Type
RESULT
Cha MJ, Lee HY, Lee KS, Jeong JY, Han J, Shim YM, Hwang HS. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014 Mar;147(3):921-928.e2. doi: 10.1016/j.jtcvs.2013.09.045. Epub 2013 Nov 4.
Reference Type
RESULT
Matsuoka Y, Yurugi Y, Takagi Y, Wakahara M, Kubouchi Y, Sakabe T, Haruki T, Araki K, Taniguchi Y, Nakamura H, Umekita Y. Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring </=3 cm. Anticancer Res. 2016 Sep;36(9):4923-30. doi: 10.21873/anticanres.11058.
Reference Type
RESULT
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004 Apr 22;350(17):1713-21. doi: 10.1056/NEJMoa032792.
Reference Type
RESULT
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. doi: 10.1016/S1470-2045(06)70804-X.
Reference Type
RESULT
Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.
Reference Type
RESULT
Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. doi: 10.1200/JCO.2009.23.2272. Epub 2009 Nov 23.
Reference Type
RESULT
Wood SL, Pernemalm M, Crosbie PA, Whetton AD. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev. 2015 Apr;41(4):361-75. doi: 10.1016/j.ctrv.2015.02.008. Epub 2015 Feb 20.
Reference Type
RESULT
Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
Reference Type
RESULT
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
Reference Type
RESULT
Duan GC, Zhang XP, Wang HE, Wang ZK, Zhang H, Yu L, Xue WF, Xin ZF, Hu ZH, Zhao QT. Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer. Onco Targets Ther. 2020 Mar 4;13:1931-1939. doi: 10.2147/OTT.S241956. eCollection 2020.
Reference Type
RESULT
Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.
Reference Type
RESULT
Thornblade LW, Mulligan MS, Odem-Davis K, Hwang B, Waworuntu RL, Wolff EM, Kessler L, Wood DE, Farjah F. Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Nov;106(5):1460-1467. doi: 10.1016/j.athoracsur.2018.06.022. Epub 2018 Jul 19.
Reference Type
RESULT
Okumura Y, Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Kondo N, Hasegawa S. Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. Ann Thorac Surg. 2009 Jun;87(6):1669-75. doi: 10.1016/j.athoracsur.2009.03.073.
Reference Type
RESULT
Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Sci Rep. 2016 Aug 17;6:31423. doi: 10.1038/srep31423.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202202172B0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
NCT07250360
COMPLETED
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
NCT07215026
ENROLLING_BY_INVITATION
A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy
NCT03130192
UNKNOWN
A Study in Non-Small Cell Lung Cancer
NCT07174388
RECRUITING
Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer
NCT03724500
UNKNOWN
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
NCT02380196
COMPLETED
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
NCT02647164
UNKNOWN
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
NCT07026669
RECRUITING
Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01517971
COMPLETED
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
NCT05066945
NOT_YET_RECRUITING
Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
NCT01294280
COMPLETED
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
NCT07057102
RECRUITING
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
NCT03791034
RECRUITING
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
NCT01052818
UNKNOWN
Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy
NCT02155426
UNKNOWN
Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer
NCT06907160
RECRUITING
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
NCT04229121
UNKNOWN
Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma
NCT05194605
UNKNOWN
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
NCT03926260
COMPLETED
NA
Perioperative Treatment Outcomes of Early NSCLC
NCT06610240
ENROLLING_BY_INVITATION
Factors Determining the Prognosis in NSCLC Stage IV
NCT04306094
UNKNOWN
Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer
NCT07042867
NOT_YET_RECRUITING
NA